Unicycive - Public Comps and Valuation Multiples

Unicycive Overview

About Unicycive

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Founded

2016

HQ

Employees

Website

unicycive.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

Last FY Revenue n/a

Last FY EBITDA -$36.2M

EV

$79.5M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Unicycive Financials

In the same period, Unicycive achieved -$23.7M in LTM net income.

See Unicycive valuation multiples based on analyst estimates

Unicycive P&L

In the most recent fiscal year, Unicycive reported EBITDA of -$36.2M.

Unicycive expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Unicycive valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	n/a	XXX	n/a	XXX	XXX	XXX
Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
Gross Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA	n/a	XXX	-$36.2M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBIT	-$30.1M	XXX	-$32.1M	XXX	XXX	XXX
EBIT Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Profit	-$23.7M	XXX	-$36.7M	XXX	XXX	XXX
Net Margin	n/a	XXX	n/a	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Unicycive including revenue, profitability, and margin analysis across different time periods.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	n/a	Analyst estimates available to subscribers	-$36.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$30.1M	Analyst estimates available to subscribers	-$32.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$23.7M	Analyst estimates available to subscribers	-$36.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	n/a	Analyst estimates available to subscribers	n/a	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Unicycive

This financial data table provides comprehensive performance metrics for Unicycive, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

Fiscal year EBITDA was -$36.2M.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Unicycive. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Unicycive Stock Performance

Unicycive has current market cap of $122M, and EV of $79.5M.

Market Cap Evolution

Unicycive Stock Data

As of November 14, 2025, Unicycive's stock price is $6.

See Unicycive trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$79.5M	$122M	XXX	XXX	XXX	XXX	$-2.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Unicycive Valuation Multiples

Unicycive's trades at 117.7x EV/Revenue multiple, and -2.2x EV/EBITDA.

See valuation multiples for Unicycive and 15K+ public comps

Unicycive Financial Valuation Multiples

As of November 14, 2025, Unicycive has market cap of $122M and EV of $79.5M.

Equity research analysts estimate Unicycive's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Unicycive has a P/E ratio of -5.1x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$122M	XXX	$122M	XXX	XXX	XXX
EV (current)	$79.5M	XXX	$79.5M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	117.7x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-2.2x	XXX	XXX	XXX
EV/EBIT	-2.6x	XXX	-2.5x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-5.1x	XXX	-3.3x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-2.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Unicycive Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Unicycive Margins & Growth Rates

Unicycive's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.4M for the same period.

Unicycive's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Unicycive's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Unicycive and other 15K+ public comps

Unicycive Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	n/a	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial